1Kisli E,Baser M,Aydin M. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis[J].{H}Hepato-Gastroenterology,2007,(73):250-253. 被引量：1
2Tzovaras G,Shukla P,Kow L. What are the risks of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography[J].{H}AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY,2000,(11):778-782. 被引量：1
3Testoni PA. Pharmacological prevention of post-ERCP pancreatitis:the facts and the fiction[J].JOP,2004,(04):171-178. 被引量：1
4Silviera ML,Seamon MJ,Porshinsky B. Complications related to endoscopic retrograde cholangiopancreatography:a comprehensive clinical review[J].J Gastrointestin Liver Dis,2009,(01):73-82. 被引量：1
5Andriuli A,Caruso N,Quitadamo M. Antisecretory vs.antiproteasic drugs in the prevention of post-ERCP pancreatitis:the evidence-based medicine derived from a meta-analysis study[J].JOP,2003,(01):41-48. 被引量：1
6Katsinelos P,Kountouras I,Chatzis J. High-dose allopurinol for prevention of post-ERCP pancreatitis:a prospective randomized double-blind controlled trial[J].{H}Gastrointestinal Endoscopy,2005,(03):407-415. 被引量：1
7Choudhary A,Bechtold M L,Arif M. Pancreatic stents for prophylaxis against post-ERCP pancreatitis:a meta-analysis and systematic review[J].{H}Gastrointestinal Endoscopy,2011,(02):275-282. 被引量：1
8Mazaki T,Masuda H,Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis:a systematic review and metaanalysis[J].{H}ENDOSCOPY,2010,(10):842-853. 被引量：1
9Das A,Singh P,Sivak MV Jr. Pancreatic-stent placement for prevention of post-ERCP pancreatitis:a cost-effectiveness analysis[J].{H}Gastrointestinal Endoscopy,2007,(07):960-968. 被引量：1
10Poon RT,Yeung C,Liu CL. Intravenous bolus somatostatin after diagnostic cholangiopancreaticography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreaticography procedures:a randomized controlled trial[J].{H}GUT,2003,(12):1768-1773. 被引量：1
